BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15926006)

  • 1. Early triptan intervention in migraine: an overview.
    Moschiano F; D'Amico D; Allais G; Rigamonti A; Melzi P; Schieroni F; Bussone G
    Neurol Sci; 2005 May; 26 Suppl 2():s108-10. PubMed ID: 15926006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of clinical trials using early acute intervention with oral triptans for migraine management.
    Dowson AJ; Mathew NT; Pascual J
    Int J Clin Pract; 2006 Jun; 60(6):698-706. PubMed ID: 16805756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of early triptan therapy for migraine.
    Láinez M
    Cephalalgia; 2004; 24 Suppl 2():24-30. PubMed ID: 15595991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
    Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
    Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.
    Cady RK; Freitag FG; Mathew NT; Elkind AH; Mao L; Fisher AC; Biondi DM; Finlayson G; Greenberg SJ; Hulihan JF
    Headache; 2009 Mar; 49(3):350-63. PubMed ID: 19220503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
    Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
    Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
    Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
    Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Almotriptan for the treatment of acute migraine: a review of early intervention trials.
    Antonaci F; De Cillis I; Cuzzoni MG; Allena M
    Expert Rev Neurother; 2010 Mar; 10(3):351-64. PubMed ID: 20187858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
    Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
    Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction?
    D'Amico D; Moschiano F; Bussone G
    Expert Rev Neurother; 2006 Jul; 6(7):1087-97. PubMed ID: 16831121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
    Winner P; Landy S; Richardson M; Ames M
    Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
    Goadsby PJ
    Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment in migraine: how strong is the current evidence?
    Gendolla A
    Cephalalgia; 2008 Sep; 28 Suppl 2():28-35. PubMed ID: 18715330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Almotriptan: meeting today's needs in acute migraine treatment.
    Láinez MJ
    Expert Rev Neurother; 2007 Dec; 7(12):1659-73. PubMed ID: 18052762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the benefits of the AwM study in the clinic.
    Dodick DW
    Cephalalgia; 2008 Sep; 28 Suppl 2():42-9. PubMed ID: 18715332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
    Burstein R; Collins B; Jakubowski M
    Ann Neurol; 2004 Jan; 55(1):19-26. PubMed ID: 14705108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What do patients want from acute migraine treatment?
    Gallagher R
    Cephalalgia; 2004; 24 Suppl 2():8-15. PubMed ID: 15595989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
    Sandrini G; Dahlöf CG; Mathew N; Nappi G
    Int J Clin Pract; 2005 Nov; 59(11):1356-65. PubMed ID: 16236092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
    Diener HC
    Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.